nodes	percent_of_prediction	percent_of_DWPC	metapath
Linezolid—MAOB—prostate gland—urinary bladder cancer	0.00749	0.118	CbGeAlD
Linezolid—MAOA—prostate gland—urinary bladder cancer	0.00639	0.101	CbGeAlD
Linezolid—MAOB—seminal vesicle—urinary bladder cancer	0.00633	0.1	CbGeAlD
Linezolid—MAOA—seminal vesicle—urinary bladder cancer	0.0054	0.0855	CbGeAlD
Linezolid—MAOB—renal system—urinary bladder cancer	0.0051	0.0807	CbGeAlD
Linezolid—MAOB—urethra—urinary bladder cancer	0.00501	0.0793	CbGeAlD
Linezolid—MAOA—renal system—urinary bladder cancer	0.00435	0.0689	CbGeAlD
Linezolid—MAOA—urethra—urinary bladder cancer	0.00428	0.0677	CbGeAlD
Linezolid—MAOB—Dopamine metabolism—NQO1—urinary bladder cancer	0.00419	0.112	CbGpPWpGaD
Linezolid—MAOB—female reproductive system—urinary bladder cancer	0.00409	0.0647	CbGeAlD
Linezolid—MAOB—vagina—urinary bladder cancer	0.0037	0.0585	CbGeAlD
Linezolid—MAOA—female reproductive system—urinary bladder cancer	0.00349	0.0552	CbGeAlD
Linezolid—MAOA—vagina—urinary bladder cancer	0.00315	0.0499	CbGeAlD
Linezolid—MAOA—Dopamine metabolism—NQO1—urinary bladder cancer	0.00263	0.0702	CbGpPWpGaD
Linezolid—MAOB—lymph node—urinary bladder cancer	0.00239	0.0378	CbGeAlD
Linezolid—MAOB—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00233	0.0622	CbGpPWpGaD
Linezolid—MAOA—lymph node—urinary bladder cancer	0.00204	0.0323	CbGeAlD
Linezolid—MAOB—Biological oxidations—GSTZ1—urinary bladder cancer	0.00159	0.0423	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTO2—urinary bladder cancer	0.0015	0.0401	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—NAT1—urinary bladder cancer	0.0015	0.0401	CbGpPWpGaD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00146	0.039	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—UGT2B7—urinary bladder cancer	0.00138	0.0367	CbGpPWpGaD
Linezolid—MAOA—Oxidative Stress—NQO1—urinary bladder cancer	0.00135	0.0359	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—CYP4B1—urinary bladder cancer	0.00124	0.033	CbGpPWpGaD
Linezolid—Pancreatitis—Methotrexate—urinary bladder cancer	0.00104	0.00116	CcSEcCtD
Linezolid—MAOA—Oxidative Stress—SOD2—urinary bladder cancer	0.00104	0.0277	CbGpPWpGaD
Linezolid—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.00104	0.00115	CcSEcCtD
Linezolid—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00104	0.00115	CcSEcCtD
Linezolid—Somnolence—Fluorouracil—urinary bladder cancer	0.00103	0.00115	CcSEcCtD
Linezolid—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00103	0.00114	CcSEcCtD
Linezolid—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00102	0.00114	CcSEcCtD
Linezolid—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00102	0.00113	CcSEcCtD
Linezolid—Fatigue—Gemcitabine—urinary bladder cancer	0.00102	0.00113	CcSEcCtD
Linezolid—Gastritis—Epirubicin—urinary bladder cancer	0.00102	0.00113	CcSEcCtD
Linezolid—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.00101	0.00113	CcSEcCtD
Linezolid—Pain—Gemcitabine—urinary bladder cancer	0.00101	0.00112	CcSEcCtD
Linezolid—Constipation—Gemcitabine—urinary bladder cancer	0.00101	0.00112	CcSEcCtD
Linezolid—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00101	0.00112	CcSEcCtD
Linezolid—Pancytopenia—Methotrexate—urinary bladder cancer	0.00101	0.00112	CcSEcCtD
Linezolid—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00101	0.00112	CcSEcCtD
Linezolid—Asthenia—Thiotepa—urinary bladder cancer	0.00101	0.00112	CcSEcCtD
Linezolid—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.001	0.00112	CcSEcCtD
Linezolid—MAOA—Biological oxidations—GSTZ1—urinary bladder cancer	0.000995	0.0266	CbGpPWpGaD
Linezolid—Neutropenia—Methotrexate—urinary bladder cancer	0.000994	0.00111	CcSEcCtD
Linezolid—Pruritus—Thiotepa—urinary bladder cancer	0.000994	0.00111	CcSEcCtD
Linezolid—Pain—Fluorouracil—urinary bladder cancer	0.000993	0.0011	CcSEcCtD
Linezolid—Paraesthesia—Cisplatin—urinary bladder cancer	0.000989	0.0011	CcSEcCtD
Linezolid—MAOA—Oxidative Stress—GPX1—urinary bladder cancer	0.000989	0.0264	CbGpPWpGaD
Linezolid—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000988	0.0011	CcSEcCtD
Linezolid—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000988	0.0011	CcSEcCtD
Linezolid—Eosinophilia—Epirubicin—urinary bladder cancer	0.000985	0.00109	CcSEcCtD
Linezolid—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000983	0.00109	CcSEcCtD
Linezolid—Dyspnoea—Cisplatin—urinary bladder cancer	0.000982	0.00109	CcSEcCtD
Linezolid—Skin disorder—Etoposide—urinary bladder cancer	0.00098	0.00109	CcSEcCtD
Linezolid—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000975	0.00108	CcSEcCtD
Linezolid—Pancreatitis—Epirubicin—urinary bladder cancer	0.000975	0.00108	CcSEcCtD
Linezolid—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000969	0.00108	CcSEcCtD
Linezolid—Anorexia—Etoposide—urinary bladder cancer	0.000962	0.00107	CcSEcCtD
Linezolid—Diarrhoea—Thiotepa—urinary bladder cancer	0.000961	0.00107	CcSEcCtD
Linezolid—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000959	0.00107	CcSEcCtD
Linezolid—Decreased appetite—Cisplatin—urinary bladder cancer	0.000957	0.00106	CcSEcCtD
Linezolid—Pneumonia—Methotrexate—urinary bladder cancer	0.000953	0.00106	CcSEcCtD
Linezolid—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000951	0.00106	CcSEcCtD
Linezolid—Pancytopenia—Epirubicin—urinary bladder cancer	0.000944	0.00105	CcSEcCtD
Linezolid—MAOA—Biological oxidations—GSTO2—urinary bladder cancer	0.000943	0.0252	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—NAT1—urinary bladder cancer	0.000943	0.0252	CbGpPWpGaD
Linezolid—Gastritis—Doxorubicin—urinary bladder cancer	0.000942	0.00105	CcSEcCtD
Linezolid—Pain—Cisplatin—urinary bladder cancer	0.000942	0.00105	CcSEcCtD
Linezolid—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000939	0.00104	CcSEcCtD
Linezolid—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000939	0.00104	CcSEcCtD
Linezolid—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000934	0.00104	CcSEcCtD
Linezolid—Renal failure—Methotrexate—urinary bladder cancer	0.000931	0.00104	CcSEcCtD
Linezolid—Neutropenia—Epirubicin—urinary bladder cancer	0.00093	0.00103	CcSEcCtD
Linezolid—Dizziness—Thiotepa—urinary bladder cancer	0.000929	0.00103	CcSEcCtD
Linezolid—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000924	0.00103	CcSEcCtD
Linezolid—Stomatitis—Methotrexate—urinary bladder cancer	0.000924	0.00103	CcSEcCtD
Linezolid—Urticaria—Fluorouracil—urinary bladder cancer	0.000923	0.00103	CcSEcCtD
Linezolid—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000918	0.00102	CcSEcCtD
Linezolid—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000911	0.00101	CcSEcCtD
Linezolid—Paraesthesia—Etoposide—urinary bladder cancer	0.000906	0.00101	CcSEcCtD
Linezolid—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000902	0.001	CcSEcCtD
Linezolid—Dyspnoea—Etoposide—urinary bladder cancer	0.0009	0.001	CcSEcCtD
Linezolid—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000897	0.000998	CcSEcCtD
Linezolid—Somnolence—Etoposide—urinary bladder cancer	0.000897	0.000997	CcSEcCtD
Linezolid—Vomiting—Thiotepa—urinary bladder cancer	0.000893	0.000993	CcSEcCtD
Linezolid—Pneumonia—Epirubicin—urinary bladder cancer	0.000892	0.000992	CcSEcCtD
Linezolid—Rash—Thiotepa—urinary bladder cancer	0.000886	0.000985	CcSEcCtD
Linezolid—Dermatitis—Thiotepa—urinary bladder cancer	0.000885	0.000984	CcSEcCtD
Linezolid—Headache—Thiotepa—urinary bladder cancer	0.00088	0.000978	CcSEcCtD
Linezolid—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000879	0.000978	CcSEcCtD
Linezolid—Decreased appetite—Etoposide—urinary bladder cancer	0.000877	0.000975	CcSEcCtD
Linezolid—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000874	0.000972	CcSEcCtD
Linezolid—Renal failure—Epirubicin—urinary bladder cancer	0.000872	0.000969	CcSEcCtD
Linezolid—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000871	0.000969	CcSEcCtD
Linezolid—Body temperature increased—Cisplatin—urinary bladder cancer	0.000871	0.000968	CcSEcCtD
Linezolid—Fatigue—Etoposide—urinary bladder cancer	0.00087	0.000967	CcSEcCtD
Linezolid—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000869	0.000967	CcSEcCtD
Linezolid—Stomatitis—Epirubicin—urinary bladder cancer	0.000864	0.000961	CcSEcCtD
Linezolid—MAOA—Biological oxidations—UGT2B7—urinary bladder cancer	0.000863	0.023	CbGpPWpGaD
Linezolid—Constipation—Etoposide—urinary bladder cancer	0.000863	0.000959	CcSEcCtD
Linezolid—Pain—Etoposide—urinary bladder cancer	0.000863	0.000959	CcSEcCtD
Linezolid—Neutropenia—Doxorubicin—urinary bladder cancer	0.000861	0.000957	CcSEcCtD
Linezolid—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000855	0.000951	CcSEcCtD
Linezolid—Haemoglobin—Methotrexate—urinary bladder cancer	0.000855	0.000951	CcSEcCtD
Linezolid—Haemorrhage—Methotrexate—urinary bladder cancer	0.000851	0.000946	CcSEcCtD
Linezolid—Asthenia—Gemcitabine—urinary bladder cancer	0.000848	0.000943	CcSEcCtD
Linezolid—Pharyngitis—Methotrexate—urinary bladder cancer	0.000844	0.000939	CcSEcCtD
Linezolid—Pruritus—Gemcitabine—urinary bladder cancer	0.000836	0.00093	CcSEcCtD
Linezolid—Nausea—Thiotepa—urinary bladder cancer	0.000834	0.000928	CcSEcCtD
Linezolid—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.00083	0.000923	CcSEcCtD
Linezolid—Pneumonia—Doxorubicin—urinary bladder cancer	0.000825	0.000918	CcSEcCtD
Linezolid—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000825	0.000917	CcSEcCtD
Linezolid—MAOB—Biological oxidations—NAT2—urinary bladder cancer	0.000824	0.022	CbGpPWpGaD
Linezolid—Pruritus—Fluorouracil—urinary bladder cancer	0.000822	0.000914	CcSEcCtD
Linezolid—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000813	0.000905	CcSEcCtD
Linezolid—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000808	0.000899	CcSEcCtD
Linezolid—Renal failure—Doxorubicin—urinary bladder cancer	0.000807	0.000897	CcSEcCtD
Linezolid—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000804	0.000894	CcSEcCtD
Linezolid—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000804	0.000894	CcSEcCtD
Linezolid—Urticaria—Etoposide—urinary bladder cancer	0.000802	0.000891	CcSEcCtD
Linezolid—Haemoglobin—Epirubicin—urinary bladder cancer	0.0008	0.00089	CcSEcCtD
Linezolid—Stomatitis—Doxorubicin—urinary bladder cancer	0.0008	0.000889	CcSEcCtD
Linezolid—Abdominal pain—Etoposide—urinary bladder cancer	0.000798	0.000887	CcSEcCtD
Linezolid—Body temperature increased—Etoposide—urinary bladder cancer	0.000798	0.000887	CcSEcCtD
Linezolid—Haemorrhage—Epirubicin—urinary bladder cancer	0.000796	0.000885	CcSEcCtD
Linezolid—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000795	0.000884	CcSEcCtD
Linezolid—Tinnitus—Methotrexate—urinary bladder cancer	0.000793	0.000882	CcSEcCtD
Linezolid—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000792	0.000881	CcSEcCtD
Linezolid—Asthenia—Cisplatin—urinary bladder cancer	0.00079	0.000879	CcSEcCtD
Linezolid—Pharyngitis—Epirubicin—urinary bladder cancer	0.00079	0.000879	CcSEcCtD
Linezolid—MAOA—Biological oxidations—CYP4B1—urinary bladder cancer	0.000777	0.0207	CbGpPWpGaD
Linezolid—Dizziness—Fluorouracil—urinary bladder cancer	0.000768	0.000854	CcSEcCtD
Linezolid—Chills—Methotrexate—urinary bladder cancer	0.000763	0.000849	CcSEcCtD
Linezolid—Diarrhoea—Cisplatin—urinary bladder cancer	0.000754	0.000838	CcSEcCtD
Linezolid—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000753	0.000837	CcSEcCtD
Linezolid—Vomiting—Gemcitabine—urinary bladder cancer	0.000751	0.000835	CcSEcCtD
Linezolid—Rash—Gemcitabine—urinary bladder cancer	0.000745	0.000828	CcSEcCtD
Linezolid—Dermatitis—Gemcitabine—urinary bladder cancer	0.000744	0.000828	CcSEcCtD
Linezolid—Tinnitus—Epirubicin—urinary bladder cancer	0.000742	0.000825	CcSEcCtD
Linezolid—Erythema—Methotrexate—urinary bladder cancer	0.00074	0.000823	CcSEcCtD
Linezolid—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00074	0.000823	CcSEcCtD
Linezolid—Headache—Gemcitabine—urinary bladder cancer	0.00074	0.000823	CcSEcCtD
Linezolid—Vomiting—Fluorouracil—urinary bladder cancer	0.000739	0.000821	CcSEcCtD
Linezolid—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000737	0.000819	CcSEcCtD
Linezolid—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000733	0.000815	CcSEcCtD
Linezolid—Rash—Fluorouracil—urinary bladder cancer	0.000732	0.000815	CcSEcCtD
Linezolid—Dermatitis—Fluorouracil—urinary bladder cancer	0.000732	0.000814	CcSEcCtD
Linezolid—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000731	0.000813	CcSEcCtD
Linezolid—MAOB—Alpha-synuclein signaling—SRC—urinary bladder cancer	0.000731	0.0195	CbGpPWpGaD
Linezolid—Headache—Fluorouracil—urinary bladder cancer	0.000728	0.000809	CcSEcCtD
Linezolid—Dysgeusia—Methotrexate—urinary bladder cancer	0.000725	0.000806	CcSEcCtD
Linezolid—Asthenia—Etoposide—urinary bladder cancer	0.000724	0.000805	CcSEcCtD
Linezolid—Chills—Epirubicin—urinary bladder cancer	0.000714	0.000794	CcSEcCtD
Linezolid—Pruritus—Etoposide—urinary bladder cancer	0.000714	0.000794	CcSEcCtD
Linezolid—Nausea—Gemcitabine—urinary bladder cancer	0.000702	0.00078	CcSEcCtD
Linezolid—Vomiting—Cisplatin—urinary bladder cancer	0.0007	0.000779	CcSEcCtD
Linezolid—Vision blurred—Methotrexate—urinary bladder cancer	0.000698	0.000776	CcSEcCtD
Linezolid—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000696	0.000774	CcSEcCtD
Linezolid—Rash—Cisplatin—urinary bladder cancer	0.000694	0.000772	CcSEcCtD
Linezolid—Dermatitis—Cisplatin—urinary bladder cancer	0.000694	0.000771	CcSEcCtD
Linezolid—Erythema—Epirubicin—urinary bladder cancer	0.000693	0.000771	CcSEcCtD
Linezolid—Diarrhoea—Etoposide—urinary bladder cancer	0.00069	0.000768	CcSEcCtD
Linezolid—Nausea—Fluorouracil—urinary bladder cancer	0.00069	0.000767	CcSEcCtD
Linezolid—Tinnitus—Doxorubicin—urinary bladder cancer	0.000687	0.000764	CcSEcCtD
Linezolid—Anaemia—Methotrexate—urinary bladder cancer	0.000684	0.000761	CcSEcCtD
Linezolid—Flatulence—Epirubicin—urinary bladder cancer	0.000683	0.000759	CcSEcCtD
Linezolid—Dysgeusia—Epirubicin—urinary bladder cancer	0.000679	0.000755	CcSEcCtD
Linezolid—Dizziness—Etoposide—urinary bladder cancer	0.000667	0.000742	CcSEcCtD
Linezolid—Muscle spasms—Epirubicin—urinary bladder cancer	0.000666	0.000741	CcSEcCtD
Linezolid—Vertigo—Methotrexate—urinary bladder cancer	0.000665	0.00074	CcSEcCtD
Linezolid—Leukopenia—Methotrexate—urinary bladder cancer	0.000663	0.000737	CcSEcCtD
Linezolid—Chills—Doxorubicin—urinary bladder cancer	0.000661	0.000735	CcSEcCtD
Linezolid—MAOB—Biological oxidations—HPGDS—urinary bladder cancer	0.000659	0.0176	CbGpPWpGaD
Linezolid—Nausea—Cisplatin—urinary bladder cancer	0.000654	0.000727	CcSEcCtD
Linezolid—Vision blurred—Epirubicin—urinary bladder cancer	0.000653	0.000726	CcSEcCtD
Linezolid—Cough—Methotrexate—urinary bladder cancer	0.000646	0.000719	CcSEcCtD
Linezolid—Convulsion—Methotrexate—urinary bladder cancer	0.000642	0.000713	CcSEcCtD
Linezolid—Vomiting—Etoposide—urinary bladder cancer	0.000642	0.000713	CcSEcCtD
Linezolid—Erythema—Doxorubicin—urinary bladder cancer	0.000641	0.000713	CcSEcCtD
Linezolid—Anaemia—Epirubicin—urinary bladder cancer	0.00064	0.000712	CcSEcCtD
Linezolid—MAOB—Biological oxidations—GSTT1—urinary bladder cancer	0.000639	0.017	CbGpPWpGaD
Linezolid—Rash—Etoposide—urinary bladder cancer	0.000636	0.000707	CcSEcCtD
Linezolid—Dermatitis—Etoposide—urinary bladder cancer	0.000636	0.000707	CcSEcCtD
Linezolid—Headache—Etoposide—urinary bladder cancer	0.000632	0.000703	CcSEcCtD
Linezolid—Flatulence—Doxorubicin—urinary bladder cancer	0.000632	0.000703	CcSEcCtD
Linezolid—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000628	0.000698	CcSEcCtD
Linezolid—Vertigo—Epirubicin—urinary bladder cancer	0.000623	0.000692	CcSEcCtD
Linezolid—Leukopenia—Epirubicin—urinary bladder cancer	0.00062	0.00069	CcSEcCtD
Linezolid—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000616	0.000685	CcSEcCtD
Linezolid—Cough—Epirubicin—urinary bladder cancer	0.000605	0.000672	CcSEcCtD
Linezolid—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000604	0.000672	CcSEcCtD
Linezolid—Vision blurred—Doxorubicin—urinary bladder cancer	0.000604	0.000672	CcSEcCtD
Linezolid—Convulsion—Epirubicin—urinary bladder cancer	0.0006	0.000668	CcSEcCtD
Linezolid—Nausea—Etoposide—urinary bladder cancer	0.000599	0.000666	CcSEcCtD
Linezolid—Hypertension—Epirubicin—urinary bladder cancer	0.000598	0.000665	CcSEcCtD
Linezolid—Anaemia—Doxorubicin—urinary bladder cancer	0.000593	0.000659	CcSEcCtD
Linezolid—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000592	0.000658	CcSEcCtD
Linezolid—Skin disorder—Methotrexate—urinary bladder cancer	0.000587	0.000653	CcSEcCtD
Linezolid—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000584	0.00065	CcSEcCtD
Linezolid—Dry mouth—Epirubicin—urinary bladder cancer	0.000577	0.000642	CcSEcCtD
Linezolid—Vertigo—Doxorubicin—urinary bladder cancer	0.000576	0.000641	CcSEcCtD
Linezolid—Anorexia—Methotrexate—urinary bladder cancer	0.000576	0.000641	CcSEcCtD
Linezolid—Leukopenia—Doxorubicin—urinary bladder cancer	0.000574	0.000638	CcSEcCtD
Linezolid—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000566	0.000629	CcSEcCtD
Linezolid—Cough—Doxorubicin—urinary bladder cancer	0.00056	0.000622	CcSEcCtD
Linezolid—Convulsion—Doxorubicin—urinary bladder cancer	0.000556	0.000618	CcSEcCtD
Linezolid—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000554	0.000616	CcSEcCtD
Linezolid—Hypertension—Doxorubicin—urinary bladder cancer	0.000554	0.000616	CcSEcCtD
Linezolid—Skin disorder—Epirubicin—urinary bladder cancer	0.000549	0.000611	CcSEcCtD
Linezolid—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000547	0.000608	CcSEcCtD
Linezolid—Insomnia—Methotrexate—urinary bladder cancer	0.000547	0.000608	CcSEcCtD
Linezolid—Paraesthesia—Methotrexate—urinary bladder cancer	0.000543	0.000603	CcSEcCtD
Linezolid—Anorexia—Epirubicin—urinary bladder cancer	0.000539	0.000599	CcSEcCtD
Linezolid—Dyspnoea—Methotrexate—urinary bladder cancer	0.000539	0.000599	CcSEcCtD
Linezolid—Somnolence—Methotrexate—urinary bladder cancer	0.000537	0.000597	CcSEcCtD
Linezolid—Dry mouth—Doxorubicin—urinary bladder cancer	0.000534	0.000594	CcSEcCtD
Linezolid—Dyspepsia—Methotrexate—urinary bladder cancer	0.000532	0.000592	CcSEcCtD
Linezolid—Decreased appetite—Methotrexate—urinary bladder cancer	0.000525	0.000584	CcSEcCtD
Linezolid—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000523	0.000582	CcSEcCtD
Linezolid—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000522	0.00058	CcSEcCtD
Linezolid—Fatigue—Methotrexate—urinary bladder cancer	0.000521	0.000579	CcSEcCtD
Linezolid—MAOA—Biological oxidations—NAT2—urinary bladder cancer	0.000517	0.0138	CbGpPWpGaD
Linezolid—Pain—Methotrexate—urinary bladder cancer	0.000517	0.000575	CcSEcCtD
Linezolid—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000512	0.00057	CcSEcCtD
Linezolid—Insomnia—Epirubicin—urinary bladder cancer	0.000512	0.000569	CcSEcCtD
Linezolid—Skin disorder—Doxorubicin—urinary bladder cancer	0.000508	0.000565	CcSEcCtD
Linezolid—Paraesthesia—Epirubicin—urinary bladder cancer	0.000508	0.000565	CcSEcCtD
Linezolid—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000506	0.000563	CcSEcCtD
Linezolid—Dyspnoea—Epirubicin—urinary bladder cancer	0.000504	0.000561	CcSEcCtD
Linezolid—Somnolence—Epirubicin—urinary bladder cancer	0.000503	0.000559	CcSEcCtD
Linezolid—Anorexia—Doxorubicin—urinary bladder cancer	0.000499	0.000555	CcSEcCtD
Linezolid—Dyspepsia—Epirubicin—urinary bladder cancer	0.000498	0.000554	CcSEcCtD
Linezolid—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000494	0.00055	CcSEcCtD
Linezolid—Decreased appetite—Epirubicin—urinary bladder cancer	0.000492	0.000547	CcSEcCtD
Linezolid—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000488	0.000543	CcSEcCtD
Linezolid—Fatigue—Epirubicin—urinary bladder cancer	0.000488	0.000542	CcSEcCtD
Linezolid—Constipation—Epirubicin—urinary bladder cancer	0.000484	0.000538	CcSEcCtD
Linezolid—Pain—Epirubicin—urinary bladder cancer	0.000484	0.000538	CcSEcCtD
Linezolid—Urticaria—Methotrexate—urinary bladder cancer	0.00048	0.000534	CcSEcCtD
Linezolid—Abdominal pain—Methotrexate—urinary bladder cancer	0.000478	0.000531	CcSEcCtD
Linezolid—Body temperature increased—Methotrexate—urinary bladder cancer	0.000478	0.000531	CcSEcCtD
Linezolid—Insomnia—Doxorubicin—urinary bladder cancer	0.000473	0.000526	CcSEcCtD
Linezolid—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00047	0.000523	CcSEcCtD
Linezolid—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000467	0.000519	CcSEcCtD
Linezolid—Somnolence—Doxorubicin—urinary bladder cancer	0.000465	0.000517	CcSEcCtD
Linezolid—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000462	0.000514	CcSEcCtD
Linezolid—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000461	0.000512	CcSEcCtD
Linezolid—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000455	0.000506	CcSEcCtD
Linezolid—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000452	0.000502	CcSEcCtD
Linezolid—Fatigue—Doxorubicin—urinary bladder cancer	0.000451	0.000502	CcSEcCtD
Linezolid—Urticaria—Epirubicin—urinary bladder cancer	0.000449	0.0005	CcSEcCtD
Linezolid—Pain—Doxorubicin—urinary bladder cancer	0.000448	0.000498	CcSEcCtD
Linezolid—Constipation—Doxorubicin—urinary bladder cancer	0.000448	0.000498	CcSEcCtD
Linezolid—Body temperature increased—Epirubicin—urinary bladder cancer	0.000447	0.000497	CcSEcCtD
Linezolid—Abdominal pain—Epirubicin—urinary bladder cancer	0.000447	0.000497	CcSEcCtD
Linezolid—MAOB—Biological oxidations—GSTP1—urinary bladder cancer	0.000443	0.0118	CbGpPWpGaD
Linezolid—Asthenia—Methotrexate—urinary bladder cancer	0.000434	0.000482	CcSEcCtD
Linezolid—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000428	0.000476	CcSEcCtD
Linezolid—Pruritus—Methotrexate—urinary bladder cancer	0.000428	0.000475	CcSEcCtD
Linezolid—Urticaria—Doxorubicin—urinary bladder cancer	0.000416	0.000462	CcSEcCtD
Linezolid—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000414	0.00046	CcSEcCtD
Linezolid—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000414	0.00046	CcSEcCtD
Linezolid—Diarrhoea—Methotrexate—urinary bladder cancer	0.000413	0.00046	CcSEcCtD
Linezolid—MAOA—Biological oxidations—HPGDS—urinary bladder cancer	0.000413	0.011	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTM1—urinary bladder cancer	0.000407	0.0109	CbGpPWpGaD
Linezolid—Asthenia—Epirubicin—urinary bladder cancer	0.000406	0.000451	CcSEcCtD
Linezolid—MAOA—Biological oxidations—GSTT1—urinary bladder cancer	0.000401	0.0107	CbGpPWpGaD
Linezolid—Pruritus—Epirubicin—urinary bladder cancer	0.0004	0.000445	CcSEcCtD
Linezolid—Dizziness—Methotrexate—urinary bladder cancer	0.0004	0.000444	CcSEcCtD
Linezolid—Diarrhoea—Epirubicin—urinary bladder cancer	0.000387	0.00043	CcSEcCtD
Linezolid—Vomiting—Methotrexate—urinary bladder cancer	0.000384	0.000427	CcSEcCtD
Linezolid—Rash—Methotrexate—urinary bladder cancer	0.000381	0.000424	CcSEcCtD
Linezolid—Dermatitis—Methotrexate—urinary bladder cancer	0.000381	0.000423	CcSEcCtD
Linezolid—Headache—Methotrexate—urinary bladder cancer	0.000379	0.000421	CcSEcCtD
Linezolid—Asthenia—Doxorubicin—urinary bladder cancer	0.000375	0.000417	CcSEcCtD
Linezolid—Dizziness—Epirubicin—urinary bladder cancer	0.000374	0.000416	CcSEcCtD
Linezolid—Pruritus—Doxorubicin—urinary bladder cancer	0.00037	0.000412	CcSEcCtD
Linezolid—Vomiting—Epirubicin—urinary bladder cancer	0.00036	0.0004	CcSEcCtD
Linezolid—Nausea—Methotrexate—urinary bladder cancer	0.000359	0.000399	CcSEcCtD
Linezolid—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000358	0.000398	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000358	0.00954	CbGpPWpGaD
Linezolid—Rash—Epirubicin—urinary bladder cancer	0.000357	0.000397	CcSEcCtD
Linezolid—Dermatitis—Epirubicin—urinary bladder cancer	0.000356	0.000396	CcSEcCtD
Linezolid—Headache—Epirubicin—urinary bladder cancer	0.000354	0.000394	CcSEcCtD
Linezolid—Dizziness—Doxorubicin—urinary bladder cancer	0.000346	0.000385	CcSEcCtD
Linezolid—Nausea—Epirubicin—urinary bladder cancer	0.000336	0.000374	CcSEcCtD
Linezolid—Vomiting—Doxorubicin—urinary bladder cancer	0.000333	0.00037	CcSEcCtD
Linezolid—Rash—Doxorubicin—urinary bladder cancer	0.00033	0.000367	CcSEcCtD
Linezolid—Dermatitis—Doxorubicin—urinary bladder cancer	0.00033	0.000367	CcSEcCtD
Linezolid—Headache—Doxorubicin—urinary bladder cancer	0.000328	0.000365	CcSEcCtD
Linezolid—Nausea—Doxorubicin—urinary bladder cancer	0.000311	0.000346	CcSEcCtD
Linezolid—MAOA—Biological oxidations—GSTP1—urinary bladder cancer	0.000278	0.00741	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTZ1—urinary bladder cancer	0.000271	0.00724	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTO2—urinary bladder cancer	0.000257	0.00686	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NAT1—urinary bladder cancer	0.000257	0.00686	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTM1—urinary bladder cancer	0.000255	0.00681	CbGpPWpGaD
Linezolid—MAOB—Metabolism—UGT2B7—urinary bladder cancer	0.000235	0.00628	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CYP4B1—urinary bladder cancer	0.000212	0.00565	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SLC19A1—urinary bladder cancer	0.0002	0.00534	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PRSS3—urinary bladder cancer	0.000195	0.0052	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.00019	0.00507	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTZ1—urinary bladder cancer	0.00017	0.00454	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTO2—urinary bladder cancer	0.000161	0.00431	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NAT1—urinary bladder cancer	0.000161	0.00431	CbGpPWpGaD
Linezolid—MAOB—Metabolism—TYMP—urinary bladder cancer	0.000156	0.00416	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000151	0.00403	CbGpPWpGaD
Linezolid—MAOA—Metabolism—UGT2B7—urinary bladder cancer	0.000148	0.00394	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NAT2—urinary bladder cancer	0.000141	0.00376	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CYP4B1—urinary bladder cancer	0.000133	0.00355	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000129	0.00345	CbGpPWpGaD
Linezolid—MAOA—Metabolism—SLC19A1—urinary bladder cancer	0.000125	0.00335	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PRSS3—urinary bladder cancer	0.000122	0.00326	CbGpPWpGaD
Linezolid—MAOB—Metabolism—RRM2—urinary bladder cancer	0.000122	0.00325	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ENO2—urinary bladder cancer	0.000113	0.00301	CbGpPWpGaD
Linezolid—MAOB—Metabolism—HPGDS—urinary bladder cancer	0.000113	0.00301	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTT1—urinary bladder cancer	0.000109	0.00292	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000105	0.0028	CbGpPWpGaD
Linezolid—MAOA—Metabolism—TYMP—urinary bladder cancer	9.78e-05	0.00261	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NQO1—urinary bladder cancer	9.08e-05	0.00242	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NAT2—urinary bladder cancer	8.84e-05	0.00236	CbGpPWpGaD
Linezolid—MAOA—Metabolism—RRM2—urinary bladder cancer	7.63e-05	0.00204	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTP1—urinary bladder cancer	7.57e-05	0.00202	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	7.26e-05	0.00194	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ENO2—urinary bladder cancer	7.07e-05	0.00189	CbGpPWpGaD
Linezolid—MAOA—Metabolism—HPGDS—urinary bladder cancer	7.07e-05	0.00189	CbGpPWpGaD
Linezolid—MAOB—Metabolism—TYMS—urinary bladder cancer	7.04e-05	0.00188	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTM1—urinary bladder cancer	6.96e-05	0.00186	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NCOR1—urinary bladder cancer	6.96e-05	0.00186	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTT1—urinary bladder cancer	6.85e-05	0.00183	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GPX1—urinary bladder cancer	6.66e-05	0.00178	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ERCC2—urinary bladder cancer	6.54e-05	0.00175	CbGpPWpGaD
Linezolid—MAOB—Metabolism—MTHFR—urinary bladder cancer	6.15e-05	0.00164	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NQO1—urinary bladder cancer	5.7e-05	0.00152	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—HRAS—urinary bladder cancer	5.56e-05	0.00148	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PPARG—urinary bladder cancer	4.99e-05	0.00133	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CREBBP—urinary bladder cancer	4.79e-05	0.00128	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTP1—urinary bladder cancer	4.75e-05	0.00127	CbGpPWpGaD
Linezolid—MAOA—Metabolism—TYMS—urinary bladder cancer	4.42e-05	0.00118	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTM1—urinary bladder cancer	4.37e-05	0.00117	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NCOR1—urinary bladder cancer	4.37e-05	0.00117	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GPX1—urinary bladder cancer	4.18e-05	0.00112	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ERCC2—urinary bladder cancer	4.11e-05	0.0011	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PTGS2—urinary bladder cancer	3.92e-05	0.00105	CbGpPWpGaD
Linezolid—MAOA—Metabolism—MTHFR—urinary bladder cancer	3.86e-05	0.00103	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PTEN—urinary bladder cancer	3.42e-05	0.000913	CbGpPWpGaD
Linezolid—MAOB—Metabolism—EP300—urinary bladder cancer	3.26e-05	0.000871	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PPARG—urinary bladder cancer	3.13e-05	0.000835	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CREBBP—urinary bladder cancer	3.01e-05	0.000802	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PTGS2—urinary bladder cancer	2.46e-05	0.000657	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PTEN—urinary bladder cancer	2.15e-05	0.000573	CbGpPWpGaD
Linezolid—MAOA—Metabolism—EP300—urinary bladder cancer	2.05e-05	0.000546	CbGpPWpGaD
